Venetoclax-resistant clones display a broader resistance to standard-of-care antimyeloma agents. (A,C) Drug sensitivity screening in the KMS12PE (A) and KMS27 (C) cell models. Cell viability was assessed by CTG after 48 hours of treatment and represented as percentage of cell killing compared with untreated cells. The parental bar represents the median cell killing of triplicated data. The resistant clones represent the median cell killing of all the clones tested with triplicated data (12A, 12B, 12C, and 12D in KMS12PE model; and 27B, 27D in KMS27 model). Two-way ANOVA was used to calculate P values. (B,D) IC₅₀ ratios of venetoclax-resistant clones to parental cells for the indicated drugs are depicted (<1: sensitive than parental and >1: resistant than parental).